StockWatch
·
GUJARAT ALKALIES & CHEMICALS LTD. · QQ2 FY-2027 · THE CALL

2-decade revenue high; PAT surges 405%, FY31 target on execution

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsGUJALKALIGUJARAT ALKALIES & CHEMICALS LTD.17 Nov 2026 · 6 min read
Verdict

Buy

confidence 7/10

Credibility

Grade B

First formal guidance; Q2 numbers delivered as stated; H1 turnaround achieved (₹36 Cr loss to ₹8 Cr profit).

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong Q2 delivery: revenue +25% YoY, PAT +405% YoY; credible FY31 aspiration (INR10K+ Cr at 20%+ EBITDA) with concrete capex pipeline. Key risk: commodity cycle volatility and capex execution.

₹1358 Cr

Revenue · +25.3% YoY

₹79 Cr

Reported PAT · +405.3% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue INR1,358 Cr vs INR1,083 Cr prior year

MET

Delivered result: INR1,357.5 Cr, YoY +25.3%

EBITDA INR222 Cr (15.74% margin)

MET

Implied from results; EBITDA margin improved from 11.6% YoY

PAT INR79 Cr from INR16 Cr prior year

MET

Delivered: INR82.6 Cr (minor rounding difference in call vs filing)

H1 sales INR2,559.63 Cr, highest in two decades

MET

Specific historical claim; corroborated by Q2 FY27 delivery

Earnings quality

What changed since the last call

Deltas vs. the prior call

Profitability turnaround

Upgrade

H1 FY26 loss ₹36 Cr swung to H1 FY27 profit ₹8 Cr; Q2 PAT ₹79 Cr from ₹16 Cr (405% YoY).

Renewable energy mix

Upgrade

Renewable penetration increased from 38% (Q2 FY26) to 55% (Q2 FY27); power cost trajectory improved.

Value-added product shift

Upgrade

Value-added products now 61% of Q2 sales vs lower prior year; command pricing premiums (chlorotoluene +100% YoY).

Domestic demand acceleration

Upgrade

Domestic sales +29% YoY in Q2; exports +14%; market diversification improving.

Chlorine integration progress

Neutral

Now 45% of capacity; target 75% by FY29 as HCl units commission.

The Q&A

Analysts pressed on capacity utilization splits, chlorine realization impact, power cost trajectory, capex details, and product-specific volumes. Management provided operational metrics (92% utilization, 45% chlorine integration, 55% renewable) but appropriately deferred commercially sensitive data to investor presentations.

The exchanges that mattered

Capacity utilization — Saket Kapoor, Kapoor & Co

Answered

92% average; Chlorotoluene ramp to ~90%; grid disturbances affected some periods; plants with higher realization performing well

Chlorine realization — Saket Kapoor, Kapoor & Co

Partial

Positive Q2 outcome; chlorine prices substantially negative which improved ECU levels significantly

Power cost trajectory — Saket Kapoor, Kapoor & Co

Answered

Slight H1 increase vs budget but INR0.57/kWh reduction vs H1 FY26; DISCOM impact INR0.45; renewable share increased; long-term target INR6

Value-added product contribution — Nirav Jimudia, Anvil Wealth

Answered

Value-added 61% of Q2 sales; chlorotoluene strong pricing uplift, phosphoric acid +44%, hydrogen peroxide +31%, caustic +10%

Caustic export market — Resham Jain, VVD Asset Managers

Answered

India #3 caustic producer; European capacity phasing; India well-positioned for US and Asian markets; solid and liquid caustic exports growing

Chloromethane dynamics — Resham Jain, VVD Asset Managers

Partial

R22 phasing near completion; R132 many capacities coming; methylene chloride major component; promising portfolio in current market

Product volumes — Vipul Shah, Sumangal Investments

Dodged

Volume details shared separately; product revenue share in investor presentation; capex details with Board approvals

Capex and funding — Vipul Shah, Sumangal Investments

Partial

Board approved projects with specific numbers in investor presentation; mix of internal accruals and borrowings; difficult to give precise number now

Guidance

Forward guidance and management's confidence

FY27-28 capex: 200 TPD caustic, 120 TPD HCl, food phosphoric acid expansion

High

Board approved; timelines Dec 2026 (caustic) and Jan 2027 (HCl); projects in pipeline with identified suppliers

Chlorine integration to 75% by FY29 (2-3 years)

Medium

Currently 45%; depends on HCl unit commissioning and downstream integration; long-term capex plan in place

FY31 aspiration: INR10,000+ Cr revenue with 20%+ EBITDA

Medium

Medium-term aspiration under Project Ahvaan; depends on project execution and commodity cycle; not formal guidance

Target EBITDA margins 20%+ by FY31 from current 16%

Medium

Drivers: chlorine integration, renewable energy cost reduction, asset productivity, value-added product mix shift

Power cost reduction to INR6/kWh by Mar 2027 from INR6.95/kWh

Medium

Renewable expansion to 60%; long-term target <INR6/kWh with 80% RE penetration by FY31

FY27-28: 200 TPD caustic flaking, 120 TPD HCl, food phosphoric acid capex

High

Dahej 200 TPD Dec 2026; HCl Jan 2027; Board approved, funding from accruals + borrowings

FY28-29: Chlorotoluene downstream, KOH, electronic-grade H2O2 projects

Medium

Project timeline FY28, funding in progress; Board seeking approvals for specific capex amounts

Risks the call surfaced

Ranked by how much they should concern a holder

Commodity price volatility

Medium

Caustic soda and chlorine are commodity chemicals highly dependent on global industrial production cycles. Q2 chlorine prices were 'substantially negative' impacting realization.

Capex execution risk

Medium

Multiple projects with tight timelines: 200 TPD caustic flaking (Dec 2026), 120 TPD HCl (Jan 2027), Chlorotoluene, food phosphoric acid. Delays would push margin improvement targets.

Power cost inflation

Medium

Power 20-30% of COGS; DISCOM hikes (INR0.45/kWh observed) and grid disturbances impact quarterly profitability. Currently 43% grid-dependent.

Competitive capacity additions

Medium

Management mentioned 'two large private corporates coming up with huge facilities of caustic soda in the near or medium term.' This could increase market competition and pressure pricing.

Early-stage venture risks

Medium

GNAL (caustic JV with NALCO) moved to profitability but higher quarterly volatility. Hydrazine sole Indian producer but pilot/commercialization stage with uncertain timeline.

Management

Score 7/10. Clear on strategic direction and operational metrics (92% capacity utilization, 55% renewable energy, 45% chlorine integration); transparent on challenges (cyclical nature, power costs, capex execution risk); appropriately guards commercially sensitive details. H1 FY27 turnaround delivered (loss to ₹8 Cr profit); Q2 targets hit (revenue, EBITDA, PAT); capex projects Board-approved with Dec 2026-Jan 2027 timelines; renewable energy penetration increased (38% to 55%); first guidance cycle, track record pending.

What to watch next
  • 1 · Dec 2026

    200 TPD caustic flaking facility commissioned at Dahej

  • 2 · Jan 2027

    120 TPD HCl synthesis unit commissioned

  • 3 · Mar 2027

    Power cost INR6/kWh with 60% renewable energy

Key risk: commodity cycle volatility and capex execution.

Informational and educational content only. Not investment advice.